Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases Journal Article

   


Authors: Buisman, F. E.; van der Stok, E. P.; Galjart, B.; Vermeulen, P. B.; Balachandran, V. P.; Coebergh van den Braak, R. R. J.; Creasy, J. M.; Höppener, D. J.; Jarnagin, W. R.; Kingham, T. P.; Nierop, P. M. H.; Sadot, E.; Shia, J.; Groot Koerkamp, B.; Grünhagen, D. J.; D’Angelica, M.; Verhoef, C.
Article Title: Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases
Abstract: Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p < 0.001), and not in desmoplastic patients (adjusted HR 1.78, 95% CI 0.75–4.21, p = 0.19). In pretreated patients no significant effect of adjuvant CTx was observed, neither in the desmoplastic group (adjusted HR 0.83, 95% CI 0.49–1.42, p = 0.50) nor in the non-desmoplastic group (adjusted HR 0.96, 95% CI 0.71–1.29, p = 0.79). Similar results were found for DFS, with a superior DFS in non-desmoplastic patients treated with adjuvant CTx (HR 0.71, 95% CI 0.55–0.93, p < 0.001) that were not pretreated. Adjuvant CTx seems to improve OS and DFS after resection of non-desmoplastic CRLM. However, this effect was only observed in patients that were not treated with chemotherapy. © 2020, The Author(s).
Keywords: chemotherapy; colorectal cancer; colorectal liver metastases; histopathological growth pattern
Journal Title: Clinical and Experimental Metastasis
Volume: 37
Issue: 5
ISSN: 0262-0898
Publisher: Springer  
Date Published: 2020-10-01
Start Page: 593
End Page: 605
Language: English
DOI: 10.1007/s10585-020-10048-w
PUBMED: 32691187
PROVIDER: scopus
PMCID: PMC7497305
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088945325&doi=10.1007%2fs10585-020-10048-w&partnerID=40&md5=ba041dde037aab77624c87c9c55d90fb
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jinru Shia
    720 Shia
  2. William R Jarnagin
    903 Jarnagin
  3. Michael D'Angelica
    777 D'Angelica
  4. T Peter Kingham
    609 Kingham
  5. Vinod P Balachandran
    252 Balachandran
  6. Eran Sadot
    38 Sadot
  7. John Creasy
    15 Creasy
Related MSK Work